Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
J Neuroimmune Pharmacol. 2021 Mar;16(1):12-37. doi: 10.1007/s11481-020-09968-x. Epub 2021 Jan 6.
The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.
由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）人际传播引起的 COVID-19 大流行已在全球范围内影响了超过 3800 万人。针对 SARS-CoV-2 的治疗和预防策略仍然是一个重大挑战。在过去的几个月中，已经出现了有效的治疗选择，现在包括了已批准用于其他用途的抗病毒药物、皮质类固醇和病毒特异性抗体。后者包括恢复期血浆和单克隆抗体。有效的、安全的和预防性疫苗将实现完全消灭病毒。现在，对针对 SARS-CoV-2 的正在提供或即将开发的每一种药物治疗和预防策略进行全面总结。
